Amneal Pharmaceuticals, Inc.
NYSE:AMRX
9.73 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 2,793.957 | 2,393.607 | 2,212.304 | 2,093.669 | 1,992.523 |
| Cost of Revenue
| 1,773.519 | 1,529.738 | 1,427.596 | 1,309.72 | 1,364.13 |
| Gross Profit
| 1,020.438 | 820.565 | 791.461 | 783.949 | 628.393 |
| Gross Profit Ratio
| 0.365 | 0.343 | 0.358 | 0.374 | 0.315 |
| Reseach & Development Expenses
| 190.714 | 194.75 | 200.046 | 209.563 | 190.585 |
| General & Administrative Expenses
| 442.036 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 34.4 | 0 | 0 | 0 | 0 |
| SG&A
| 476.436 | 429.675 | 399.7 | 365.504 | 326.727 |
| Other Expenses
| 103.962 | 18.738 | -3.96 | 41.19 | 19.926 |
| Operating Expenses
| 771.112 | 659.495 | 595.786 | 616.257 | 537.238 |
| Operating Income
| 249.326 | 204.374 | -94.928 | 152.716 | 91.155 |
| Operating Income Ratio
| 0.089 | 0.085 | -0.043 | 0.073 | 0.046 |
| Total Other Income Expenses Net
| -304.339 | -244.644 | -153.199 | -121.35 | -126.935 |
| Income Before Tax
| -55.013 | -40.27 | -248.127 | 31.366 | -35.78 |
| Income Before Tax Ratio
| -0.02 | -0.017 | -0.112 | 0.015 | -0.018 |
| Income Tax Expense
| 18.863 | 8.452 | 6.662 | 11.196 | -104.358 |
| Net Income
| -116.886 | -83.993 | -129.986 | 10.624 | 91.059 |
| Net Income Ratio
| -0.042 | -0.035 | -0.059 | 0.005 | 0.046 |
| EPS
| -0.38 | -0.48 | -0.86 | 0.07 | 0.62 |
| EPS Diluted
| -0.38 | -0.48 | -0.86 | 0.07 | 0.61 |
| EBITDA
| 439.773 | 399.759 | 150.425 | 401.097 | 345.605 |
| EBITDA Ratio
| 0.157 | 0.167 | 0.068 | 0.192 | 0.173 |